Enanta Pharmaceuticals, Inc. (ENTA) Financials

ENTA Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 296.9 million 195.8 million
March 31, 2026 314.7 million 198.1 million
Dec. 31, 2025 329.5 million 202.9 million
Sept. 30, 2025 280.7 million 216.0 million

ENTA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -10.0 million 3.7 million
March 31, 2026 -7.2 million 3.7 million
Dec. 31, 2025 -11.8 million 3.8 million
Sept. 30, 2025 -7.9 million 4.0 million

ENTA Net Income

No data available :(

ENTA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 189.5 million - 55.7 million
March 31, 2026 163.8 million 98.6 million 52.8 million
Dec. 31, 2025 185.8 million 104.1 million 57.1 million
Sept. 30, 2025 188.9 million 112.4 million 57.9 million

ENTA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 29.1 million
March 31, 2026 29.0 million
Dec. 31, 2025 28.7 million
Sept. 30, 2025 21.4 million

ENTA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 7000 22.1 million 9.5 million -
March 31, 2026 15000 19.4 million 9.6 million -
Dec. 31, 2025 143000 20.9 million 9.0 million -
Sept. 30, 2025 1.5 million 23.8 million 9.7 million -

ENTA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 14.4 million 1.2 million
March 31, 2026 17.2 million 1.2 million
Dec. 31, 2025 18.6 million -
Sept. 30, 2025 15.1 million 1.3 million

ENTA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ENTA

Price: $12.83

52 week price:
6.45
17.15

Earnings Per Share: -2.42 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 3045

Ebitda: 15.9 million

Market Capitalization: 383.3 million

Links: